Pre-computed peptide candidates for pharmacogenomic variants
Sample: 5 of 50 variantsGenerated: March 2026Version 1.0
rs1801133MTHFRCPIC A
C677T (Ala222Val)
Folate metabolism, methotrexate response, neural tube defect risk. Most studied pharmacogenomic variant worldwide. Reduced enzyme activity leads to elevated homocysteine.
Top candidate
ANRKVATNNA
Binding affinity8.1
Structural confidence7.5
Clinical relevance9.0
Novelty6.8
Synthesizability8.2
Protease stability6.5
Cell permeability5.9
Half-life6.0
Target selectivity7.4
Aggregation risk7.8
rs4244285CYP2C19CPIC A
CYP2C19*2 (G681A, splicing defect)
No-function allele. Primary cause of clopidogrel non-response. Affects proton pump inhibitor metabolism, voriconazole dosing, and SSRI response.
Top candidate
LEKRAVTNNASNKVDLA
Binding affinity7.3
Structural confidence7.1
Clinical relevance8.5
Novelty5.9
Synthesizability7.8
Protease stability6.2
Cell permeability5.5
Half-life6.3
Target selectivity7.0
Aggregation risk7.4
rs1799853CYP2C9CPIC A
CYP2C9*2 (C430T, Arg144Cys)
Decreased-function allele. Critical for warfarin dosing algorithms. Also affects NSAID metabolism, phenytoin clearance, and sulfonylurea response.
Top candidate
VPNTNKKVDA
Binding affinity7.8
Structural confidence6.9
Clinical relevance8.8
Novelty6.1
Synthesizability7.5
Protease stability6.7
Cell permeability5.8
Half-life6.4
Target selectivity7.2
Aggregation risk6.8
rs9923231VKORC1CPIC A
VKORC1 -1639G>A (promoter)
Major determinant of warfarin dose requirements. Explains ~25% of warfarin dose variability. Part of FDA-mandated pharmacogenomic labeling.
Top candidate
KRADLVTNNQE
Binding affinity7.0
Structural confidence7.3
Clinical relevance8.2
Novelty5.7
Synthesizability7.9
Protease stability6.0
Cell permeability5.6
Half-life6.1
Target selectivity6.8
Aggregation risk7.5
rs429358APOEFDA B
APOE4 (Cys112Arg)
Major genetic risk factor for late-onset Alzheimer's disease. Affects lipid transport, statin response, and amyloid-beta clearance. Therapeutic peptide target for neuroprotection.
Top candidate
RGELVQALRN
Binding affinity8.4
Structural confidence7.8
Clinical relevance9.2
Novelty7.1
Synthesizability7.0
Protease stability6.9
Cell permeability6.2
Half-life6.5
Target selectivity7.6
Aggregation risk7.3
This is a sample of 5 variants
The full PGx Atlas contains 50 clinically validated variants with 141 ranked peptide candidates,
ESMFold 3D structures, and Fmoc-SPPS synthesis protocols.